Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)

PHASE2TerminatedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

July 8, 2022

Primary Completion Date

June 26, 2024

Study Completion Date

June 26, 2024

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Magrolimab

Administered intravenous infusion

DRUG

Bevacizumab

Administered intravenous infusion

DRUG

Irinotecan

Administered intravenous infusion

DRUG

Fluorouracil

Administered intravenous infusion

DRUG

Leucovorin

Administered intravenous infusion

Trial Locations (51)

0

Hong Kong Integrated Oncology Centre, Hong Kong

2010

Kinghorn Cancer Centre, Darlinghurst

2065

Genesis Care North Shore, St Leonards

2148

Westmead Hospital, Blacktown

2228

Southside Cancer Care Centre, Miranda

3004

The Alfred Hospital, Melbourne

3084

Austin Health, Heidelberg

4102

Princess Alexandra Hospital, Woolloongabba

5042

Flinders Medical Centre, Bedford Park

6800

Centre Hospitalizer De L'Ardenne, Libramont-Chevigny

7100

Hôpital de Jolimont, Haine-Saint-Paul

8035

Hospital Universitari Vall d'Hebron, Barcelona

8908

Institut Català d'Oncologia- Hospital Duran I Reynals, L'Hospitalet de Llobregat

13057

Hematology Oncology Associates of Central New York, PC, East Syracuse

14263

Roswell Park Cancer Institute, Buffalo

14642

AdventHealth, Rochester

19104

Pennsylvania Hospital, Philadelphia

19111

Fox Chase Cancer Center, Philadelphia

22205

Virginia Cancer Specialists, PC, Arlington

25030

Centre Hospitalier Regional Universitaire Hopital Besancon, Besançon

28007

Hospital General Universitario Gregorio Marañón, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

28050

Hospital HM Sanchinarro, Madrid

32806

Orlando Health Cancer Institute, Orlando

35128

Istituto Oncologico Veneto (IOV)- IRCCS, Padua

36100

San Bortolo General Hospital- Oncology Department, Vicenza

37000

CHU de Tours, Tours

46845

Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne

47014

"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - Medical Oncology Department", Meldola

48106

University of Michigan, Ann Arbor

56126

Azienda Ospedaliera Universitaria Pisana- UO Oncologia Medica, Pisa

57105

Avera Cancer Institute, Sioux Falls

66205

University of Kansas, Westwood

69008

Centre Léon Bérard - Centre de Lutte contre le Cancer, Lyon

71013

Istituto di Ricovero e Cura a Carattere Scientifico - Istituto Clinico Humanitas, San Giovanni Rotondo

75012

Hopital franco brittanique, Paris

75246

Texas Oncology, Dallas

77030

Baylor College of Medicine Medical Center, Houston

81675

Klinikum rechts der Isar der TU Munchen Zentrum fur klinische Studien der Klinik und Poliklinik fur Innere Medizin III, München

90033

USC Norris Comprehensive Cancer Center, Los Angeles

90095

University of California Los Angeles (UCLA), Santa Monica

90277

Torrance Memorial Physician Network, Redondo Beach

91010

City of Hope ( City of Hope National Medical Center, City of Hope Medical Center ), Duarte

94305

Stanford Cancer Center, Palo Alto

98103

Seattle Cancer Care Alliance (SCCA), Seattle

327203

Sarah Cannon Research Institute, Nashville

K1H 8L6

The Ottawa Hospital Cancer Centre, Ottawa

M5G 1X6

Princess Margaret Cancer Centre, Toronto

01307

Carl Gustav Carus Management GMBH, Dresden

Unknown

Queen Mary Hospital, Hong Kong

00902

Pan American Center for Oncology Trials, LLC, San Juan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT05330429 - Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) | Biotech Hunter | Biotech Hunter